Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02738775 · ClinicalTrials.gov registry record · Phase 2
Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis
A Phase 2 study, sponsored by TG Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT02738775 is a Phase 2 study that has completed, run by TG Therapeutics. The registered enrollment target is 49 participants.
The verdict
NCT02738775, a Phase 2 study, has completed, sponsored by TG Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
This study evaluates the use of single agent ublituximab, a novel monoclonal antibody, in participants with relapsing forms of multiple sclerosis.
Interventions
- DRUG Placebo
- BIOLOGICAL Ublituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2016-05-27 |
| Est. Completion | 2018-08-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02738775
The ClinicalTrials.gov registry entry for NCT02738775 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TG Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02738775 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02738775 about?
NCT02738775 is a clinical study titled "Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis". This study evaluates the use of single agent ublituximab, a novel monoclonal antibody, in participants with relapsing forms of multiple sclerosis.
What is the current status of trial NCT02738775?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2016-05-27. Estimated completion is 2018-08-13.
What interventions are being tested in trial NCT02738775?
The interventions under investigation include: Placebo (DRUG), Ublituximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02738775?
This trial is sponsored by TG Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.